Picroside II treatment increased the serum levels of SOD (Figure 3(a)), CAT (Figure 3(b)), and GSPx (Figure 3(c)) and reduced the serum level of MDA (Figure 3(d), P < 0.05) when compared with the MG group. Here, SOD1 is linked to myasthenia gravis.